Skip to main content
Equibles
AZR logo

AZR · Azora Therapeutics, Inc. (DE) · Investor Relations

Track AZR — free

Use AZR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AZR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.00 +0.29 (+7.82%) At close · Nov 6
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“the Company has concluded that there is substantial doubt about its ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$10.50M
Shares
2.63M
Volume · Nov 6 78.19K Avg daily vol (3M) 52.9K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-10-28 Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
2026-08-17 Adiel Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
2026-06-11 Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
2026-05-11 Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
2026-03-06 Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
2026-03-03 Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
2026-02-24 Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
2026-02-04 Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
2025-12-01 Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds
2025-11-14 Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Past events

Date Event Type
2026-06-11 Adial Pharmaceuticals Acquisition of Azora Therapeutics: Conference Call Conference
2026-02-25 Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Conference

Source: https://www.adial.com/investors/

Key facts CIK 1513525 13F (30d) 10 filings 7 filers Visit website Investor relations